cisplatin + capecitabine

DRUG2 trials

Sponsors

ASLAN Pharmaceuticals, AstraZeneca

Conditions

Esophageal Squamous Cell CarcinomaSolid Tumor

Phase 1

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

CompletedNCT02648425

ASLAN PharmaceuticalsSolid Tumor

Start: 2014-08-05End: 2017-09-15Updated: 2018-10-25

Phase 3

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

Active, not recruitingNCT04550260

AstraZenecaEsophageal Squamous Cell Carcinoma

Start: 2020-10-19End: 2027-06-30Updated: 2026-05-13

Related Papers

A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.

Journal of Clinical Oncology2022-01-1919 citations

Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.

Journal of Clinical Oncology2019-01-2914 citations

Initial signals of efficacy in cholangiocarcinoma from a phase Ib trial of varlitinib in combination with doublet chemotherapy (cisplatin + 5-fluororacil or capecitabine).

Journal of Clinical Oncology2017-05-20